Secondary acute myeloid leukemia
Characterization and Prognosis of Secondary Acute Myeloid Leukemia in an Asian Population: AML With Antecedent Hematological Disease Confers Worst Outcomes, Irrespective of Cytogenetic Risk | Anticancer Research
Effect of therapy-related acute myeloid leukemia on the outcome of patients with acute myeloid leukemia
Redefining prognostication of de novo cytogenetically normal acute myeloid leukemia in young adults | Blood Cancer Journal
Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06 | Haematologica
Common mutations in de novo and secondary AML. A number of clonal blood... | Download Scientific Diagram
Secondary vs de novo acute myeloid leukemia
Genes | Free Full-Text | Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia
A) Incidence of De Novo, Secondary, and Therapy-Related Acute Myeloid... | Download Scientific Diagram
Recurrent mutation groups in de novo AML. Genes recurrently mutated in... | Download Scientific Diagram
IJMS | Free Full-Text | Application of High Throughput Technologies in the Development of Acute Myeloid Leukemia Therapy: Challenges and Progress
Venetoclax plus intensive induction chemotherapy safe for fit, older patients with AML
Haematologica August 2021
Overall survival time in de novo AML and in t-AML. t-AML,... | Download Scientific Diagram
Decitabine shows comparable OS to standard induction chemotherapy and better safety in patients with AML
Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1 - Modern Pathology
A single-cell survey of cellular hierarchy in acute myeloid leukemia | Journal of Hematology & Oncology | Full Text
SocforHemepath on Twitter: "Another new provisional entity in the 2017 WHO: Acute Myeloid Leukemia with BCR-ABL1. This is a type of de novo AML, not to be confused with the blast phase
Characterization and Prognosis of Secondary Acute Myeloid Leukemia in an Asian Population: AML With Antecedent Hematological Disease Confers Worst Outcomes, Irrespective of Cytogenetic Risk | Anticancer Research
Mutational variation in de-novo and secondary acute myeloid Leukemia.... | Download Scientific Diagram
AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics | Leukemia
Acute Myeloid Leukemia | Oncohema Key
Key Topic Videos | MYLOTARG®▽(gemtuzumab ozogamicin) | PfizerPro UK
